Multiple variants of meningococcal protein nmb1870

US2017290902A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2017290902-A1
Application numberUS-201615351286-A
CountryUS
Kind codeA1
Filing dateNov 14, 2016
Priority dateNov 22, 2002
Publication dateOct 12, 2017
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.

First claim

Opening claim text (preview).

1 : A composition comprising at least two of the following antigens: (a) a first protein, comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 24 and/or comprising an amino acid sequence consisting of a fragment of at least 7 contiguous amino acids from SEQ ID. NO: 24; (b) a second protein, comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 33 and/or comprising an amino acid sequence consisting of a fragment of at least 7 contiguous amino acids from SEQ ID NO: 33; and (c) a third protein, comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 41 and/or comprising an amino acid sequence consisting of a fragment of at least 7 contiguous amino acids from SEQ ID NO: 41. 2 - 33 . (canceled)

Assignees

Inventors

Classifications

  • from Pasteurellaceae (F), e.g. Haemophilus influenza · CPC title

  • A61K39/095Primary

    Neisseria · CPC title

  • from Neisseriaceae (F) · CPC title

  • {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus · CPC title

  • characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2017290902A1 cover?
Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal …
Who is the assignee on this patent?
Glaxosmithkline Biologicals Sa
What technology area does this patent fall under?
Primary CPC classification A61K39/095. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Oct 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).